Sanofi-Aventis Ambien CR "Approvable"; Delay Could Be Boost For Lunesta
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Aventis' controlled-release formulation of its insomnia agent zolpidem, Ambien CR, received an FDA "approvable" letter, the company announced April 11